I 
116TH CONGRESS 
1ST SESSION H. R. 3109 
To provide grants to better understand and reduce gestational diabetes, and 
for other purposes. 
IN THE HOUSE OF REPRESENTATIVES 
JUNE 5, 2019 
Mr. ENGEL (for himself and Mr. BURGESS) introduced the following bill; 
which was referred to the Committee on Energy and Commerce 
A BILL 
To provide grants to better understand and reduce 
gestational diabetes, and for other purposes. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Gestational Diabetes 
Act of 2019’’ or the ‘‘GEDI Act’’. 
SEC. 2. GESTATIONAL DIABETES. 
Part B of title III of the Public Health Service Act 
(42 U.S.C. 243 et seq.) is amended by inserting after sec-
tion 317H the following: 
VerDate Sep 11 2014 
00:47 Jun 14, 2019
Jkt 089200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H3109.IH
H3109
pamtmann on DSKBFK8HB2PROD with BILLS
‘‘SEC. 317H–1. GESTATIONAL DIABETES. 
‘‘(a) UNDERSTANDING
AND MONITORING GESTA-
TIONAL DIABETES.— 
‘‘(1) IN
GENERAL.—The Secretary, acting 
through the Director of the Centers for Disease 
Control and Prevention, in consultation with the Di-
abetes Mellitus Interagency Coordinating Committee 
established under section 429 and representatives of 
appropriate national health organizations, shall de-
velop a multisite gestational diabetes research 
project within the diabetes program of the Centers 
for Disease Control and Prevention to expand and 
enhance surveillance data and public health research 
on gestational diabetes. 
‘‘(2) AREAS TO BE ADDRESSED.—The research 
project developed under paragraph (1) shall ad-
dress— 
‘‘(A) procedures to establish accurate and 
efficient systems for the collection of gestational 
diabetes data within each State and common-
wealth, territory, or possession of the United 
States; 
‘‘(B) the progress of collaborative activities 
with the National Vital Statistics System, the 
National Center for Health Statistics, and 
State health departments with respect to the 
VerDate Sep 11 2014 
00:47 Jun 14, 2019
Jkt 089200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H3109.IH
H3109
pamtmann on DSKBFK8HB2PROD with BILLS
standard birth certificate, in order to improve 
surveillance of gestational diabetes; 
‘‘(C) postpartum methods of tracking 
women with gestational diabetes after delivery 
as well as targeted interventions proven to 
lower the incidence of type 2 diabetes in that 
population; 
‘‘(D) variations in the distribution of diag-
nosed and undiagnosed gestational diabetes, 
and of impaired fasting glucose tolerance and 
impaired fasting glucose, within and among 
groups of women; and 
‘‘(E) factors and culturally sensitive inter-
ventions that influence risks and reduce the in-
cidence of gestational diabetes and related com-
plications during childbirth, including cultural, 
behavioral, racial, ethnic, geographic, demo-
graphic, socioeconomic, and genetic factors. 
‘‘(3) REPORT.—Not later than 2 years after the 
date of the enactment of this section, and annually 
thereafter, the Secretary shall generate a report on 
the findings and recommendations of the research 
project including prevalence of gestational diabetes 
in the multisite area and disseminate the report to 
the appropriate Federal and non-Federal agencies. 
VerDate Sep 11 2014 
00:47 Jun 14, 2019
Jkt 089200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H3109.IH
H3109
pamtmann on DSKBFK8HB2PROD with BILLS
‘‘(b) EXPANSION OF GESTATIONAL DIABETES RE-
SEARCH.— 
‘‘(1) IN GENERAL.—The Secretary shall expand 
and intensify public health research regarding gesta-
tional diabetes. Such research may include— 
‘‘(A) developing and testing novel ap-
proaches for improving postpartum diabetes 
testing or screening and for preventing type 2 
diabetes in women with a history of gestational 
diabetes; and 
‘‘(B) conducting public health research to 
further understanding of the epidemiologic, 
socioenvironmental, behavioral, translation, and 
biomedical factors and health systems that in-
fluence the risk of gestational diabetes and the 
development of type 2 diabetes in women with 
a history of gestational diabetes. 
‘‘(2) AUTHORIZATION
OF
APPROPRIATIONS.— 
There is authorized to be appropriated to carry out 
this subsection $5,000,000 for each of fiscal years 
2020 through 2024. 
‘‘(c) DEMONSTRATION GRANTS TO LOWER
THE 
RATE OF GESTATIONAL DIABETES.— 
‘‘(1) IN
GENERAL.—The Secretary, acting 
through the Director of the Centers for Disease 
VerDate Sep 11 2014 
00:47 Jun 14, 2019
Jkt 089200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H3109.IH
H3109
pamtmann on DSKBFK8HB2PROD with BILLS
‘‘(F) working to prevent gestational diabe-
tes and prevent or delay the development of 
type 2 diabetes in women with a history of ges-
tational diabetes; and 
‘‘(G) achieving outcomes designed to assess 
the efficacy and cost-effectiveness of interven-
tions that can inform decisions on long-term 
sustainability, including third-party reimburse-
ment. 
‘‘(3) APPLICATION.—An eligible entity desiring 
to receive a grant under this subsection shall submit 
to the Secretary— 
‘‘(A) an application at such time, in such 
manner, and containing such information as the 
Secretary may require; and 
‘‘(B) a plan to— 
‘‘(i) lower the rate of gestational dia-
betes during pregnancy; or 
‘‘(ii) develop methods of tracking 
women with a history of gestational diabe-
tes and develop effective interventions to 
lower the incidence of the recurrence of 
gestational diabetes in subsequent preg-
nancies and the development of type 2 dia-
betes. 
VerDate Sep 11 2014 
00:47 Jun 14, 2019
Jkt 089200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6201
E:\BILLS\H3109.IH
H3109
pamtmann on DSKBFK8HB2PROD with BILLS
‘‘(4) USES OF FUNDS.—An eligible entity re-
ceiving a grant under this subsection shall use the 
grant funds to carry out demonstration projects de-
scribed in paragraph (1), including— 
‘‘(A) expanding community-based health 
promotion education, activities, and incentives 
focused on the prevention of gestational diabe-
tes and development of type 2 diabetes in 
women with a history of gestational diabetes; 
‘‘(B) aiding State- and tribal-based diabe-
tes prevention and control programs to collect, 
analyze, disseminate, and report surveillance 
data on women with, and at risk for, gesta-
tional diabetes, the recurrence of gestational di-
abetes in subsequent pregnancies, and, for 
women with a history of gestational diabetes, 
the development of type 2 diabetes; and 
‘‘(C) training and encouraging health care 
providers— 
‘‘(i) to promote risk assessment, high- 
quality care, and self-management for ges-
tational diabetes and the recurrence of ges-
tational diabetes in subsequent preg-
nancies; and 
VerDate Sep 11 2014 
00:47 Jun 14, 2019
Jkt 089200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6201
E:\BILLS\H3109.IH
H3109
pamtmann on DSKBFK8HB2PROD with BILLS
‘‘(ii) to prevent the development of 
type 2 diabetes in women with a history of 
gestational diabetes, and its complications 
in the practice settings of the health care 
providers. 
‘‘(5) REPORT.—Not later than 4 years after the 
date of the enactment of this section, the Secretary 
shall prepare and submit to the Congress a report 
concerning the results of the demonstration projects 
conducted through the grants awarded under this 
subsection. 
‘‘(6) DEFINITION
OF
ELIGIBLE
ENTITY.—In 
this subsection, the term ‘eligible entity’ means a 
nonprofit organization (such as a nonprofit academic 
center or community health center) or a State, trib-
al, or local health agency. 
‘‘(7) AUTHORIZATION
OF
APPROPRIATIONS.— 
There is authorized to be appropriated to carry out 
this subsection $5,000,000 for each of fiscal years 
2020 through 2024. 
‘‘(d) POSTPARTUM FOLLOW-UP REGARDING GESTA-
TIONAL DIABETES.—The Secretary, acting through the 
Director of the Centers for Disease Control and Preven-
tion, shall work with the State- and tribal-based diabetes 
prevention and control programs assisted by the Centers 
VerDate Sep 11 2014 
00:47 Jun 14, 2019
Jkt 089200
PO 00000
Frm 00008
Fmt 6652
Sfmt 6201
E:\BILLS\H3109.IH
H3109
pamtmann on DSKBFK8HB2PROD with BILLS
to encourage postpartum follow-up after gestational diabe-
tes, as medically appropriate, for the purpose of reducing 
the incidence of gestational diabetes, the recurrence of 
gestational diabetes in subsequent pregnancies, the devel-
opment of type 2 diabetes in women with a history of ges-
tational diabetes, and related complications.’’. 
Æ 
VerDate Sep 11 2014 
00:47 Jun 14, 2019
Jkt 089200
PO 00000
Frm 00009
Fmt 6652
Sfmt 6301
E:\BILLS\H3109.IH
H3109
pamtmann on DSKBFK8HB2PROD with BILLS